FDA Sets Advisory Date For MGI’s Aquavan
This article was originally published in The Pink Sheet Daily
Executive Summary
Colonoscopy anesthetic could prove a reimbursement winner.
You may also be interested in...
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
MGI sale comes less than two weeks after the biopharma said it was exploring "strategic alternatives."
MGI Pharma Files Aquavan NDA
Drug for mild to moderate sedation could achieve peak sales of $400 million, company tells "The Pink Sheet" DAILY.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.